As a founding voice in the world of holistic wellness, Canyon Ranch® has the wisdom and expertise of spending nearly 40 years helping its guests achieve well-being. Now, the life-enhancement brand that’s built a devoted global following, is finally going global itself.
Under the guidance of the brand’s new Chief Executive Officer, Susan E. Docherty, the Company announced today the development of its first-ever international destination, Canyon Ranch Wellness Resort at Kaplankaya, on a spectacular peninsula of the sun-kissed Aegean coast. The initial phase of the Canyon Ranch development, which will open in July 2016, will include a strikingly modern resort and luxury real estate offerings. The property will integrate the signature wellness and lifestyle programming that has earned Canyon Ranch a famously loyal clientele worldwide.
To view the multimedia release go to:
http://www.multivu.com/players/English/7634751-canyon-ranch-resort-kaplankaya-turkey/
Today, BACARDÍ® rum unveils a fresh, new take on the brand with a 30-second TV spot, experiential House Party campaign and comprehensive digital, mobile and partnership strategy designed to connect with millennials on their terms, in their world, in their way. This is the first campaign launch since BACARDÍ revamped its advertising and marketing business four months ago and reflects the brand’s desire to dominate the category once again.
The TV spot, entitled “The Truck,” is an authentic take on a Millennial’s world, capturing the energy of their life. It features a group of friends letting nothing get in the way of hosting an amazing house party. Shot with a hand-held camera, the viewer is drawn in to feel like they are part of the story, experiencing the energy of this cross-country journey. It’s styled similar to a movie trailer, giving the audience a sneak peek into the brand world and house party occasion, then leaving you wanting to see and learn more. The ad represents the first work from BBDO and OMD, the new global creative agency partners for the Bacardi portfolio of brands.
The ad includes the tagline: “There’s Nothing in the Way,” a tribute to the brand’s history and irrepressible spirit, as well as a shout out to those who are busting through and overcoming obstacles in the real world.
To view the multimedia release go to:
http://www.multivu.com/players/English/7654851-bacardi-rum-creative-platform/
Seniors 80 and over yearn to be connected but many are not, causing a more than quarter of them to become “virtual shut-ins.” While a new survey shows use of social technology is linked to better wellbeing for people in this age group and demonstrates its potential for combating isolation, it also reveals their frustration and need for assistance in becoming part of the digital world. These findings come from a “Rewiring Aging” survey supported by Brookdale Senior Living, conducted by Kelton, a leading global insights firm in collaboration with the Stanford Center on Longevity. It is the first in-depth study of how online social networking and similar tech-based activities affect the quality of life among America’s fastest-growing demographic segment.
Fifty-eight percent of seniors surveyed believe technology can improve communication with family and friends. This belief is borne out by the findings; respondents who indicated they interact with loved ones through social technology report having higher life satisfaction and health and being more likely to attain life goals than those who do not use social technology.
To view the multimedia release go to:
http://www.multivu.com/players/English/7617951-brookdale-seniors-technology/
Lytx®, Inc., the global leader in video-based driver safety, unveiled today a giant leap forward in safe driving innovation with its Lytx ActiveVision℠ service available for select Lytx DriveCam™ clients immediately, and industry-wide in January 2016. The ActiveVision service will be publicly demonstrated this weekend at the 2015 American Trucking Associations Management Conference & Exhibition in Philadelphia.
The ActiveVision service is a revolutionary and comprehensive safety solution that helps detect and address, both in real time and over time, distracted and drowsy driving and following too close, all potentially dangerous and costly driving behaviors that often go undetected -- behaviors that contribute to 6,000 deaths, 500,000 injuries, and more than $175 billion in economic costs each year, according to the National Highway Traffic Safety Administration.
To view the multimedia release go to:
http://www.multivu.com/players/English/7277351-lytx-activevision-distracted-driving/
Global health service company Cigna today announced it is expanding access to its popular Coach by Cigna health and fitness mobile application to make it more broadly available to its clients and customers. Coach is now available on both Apple® iOS and Android™ mobile smart devices.
Currently a go-to health and fitness app for more than 350,000 users in 15 nations in nine languages, Coach by Cigna is now available at no charge in the App Store ℠ and Google Play™ stores for mobile devices that have either the Apple® iOS9 or the Android™ Lollipop operating system.
To view the multimedia release go to:
http://www.multivu.com/players/English/7448831-coach-by-cigna-fitness-app/
The Investor Desk Presents US Highland, Inc. (OTC PINK: UHLN), a diversified product development, sales, and marketing company.
Since its founding in 1997 as Highland AB in Sweden, the Texas-based company has been developing and manufacturing high-performance single cylinder and V-twin powertrains used for a variety of applications. In September 2015, the publicly traded company began diversifying its operations, guiding startups in the marketing, reselling, and distributing of their products, as well as helping customers establish their brand and penetrate the U.S. market.
Overseeing the company’s growth is chief executive officer and president Josh Whitaker, a marketing executive with global experience in technology marketing, strategy, and implementation. Whitaker has worked with high-profile brands like Red Bull and Under Armour, as well as industry leading companies like Tucker Rocky Distributing and KTM Motorcycles.
Over the past two decades, US Highland, Inc. has tapped a variety of distribution channels, enabling growing businesses, both domestic and foreign, to launch their products in the United States whether wholesale, retail, or over the Internet.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7660851-us-highland-the-investor-desks-new-company/
If there’s one thing that socially responsible businesses have learned, it’s that they can’t go at it alone. Whether it’s implementing responsible sourcing initiatives or creating a positive corporate model to make an impact on sustainability, there is strength in numbers. So where did Ben & Jerry’s turn for help and inspiration for its latest ice cream flavor? Colorado-based New Belgium Brewing. Never has the phrase “polishing off a pint” been so perfectly poised in any partnership for a delicious double-entendre.
Collectively committed to making a better impact in their global communities, the two B Corp companies proudly introduced Salted Caramel Brown-ie Ale ice cream, which will be featured in Ben & Jerry’s Scoop Shops as well as in pints across the country as a Limited Batch flavor this fall (MSRP $4.89). The concoction consists of New Belgium Brown Ale Ice Cream with Salted Caramel Swirls and Fudge Brownies. The ice cream, arriving on shelves this month, was unveiled Wednesday evening at a Washington D.C. launch “Brew-Ha-Ha” in the confines of the historic Howard Theatre. The launch event was heralded as “a night of music, climate activism, beer, and ice cream.” Musicians Galactic and Dr. Dog performed at the unveiling of Ben & Jerry’s newest ice cream flavor to highlight climate activism.
To view the multimedia release go to:
http://www.multivu.com/players/English/7648451-ben-and-jerry-s-new-belgium-brewery/
Blood is an essential component for life, but many people do not think about it until the need is critical. Each year 234 million major operations are performed worldwide, many involving blood transfusions or treatments resulting in a continuous need for donations.
That’s why Abbott (NYSE: ABT) and Real Madrid soccer star Cristiano Ronaldo are partnering to bring even more attention to this important cause. Regarded as one of the top soccer players in the world, Ronaldo will serve as the first global ambassador for the BE THE 1™ movement – developed to inspire young people around the world to regularly donate blood.
“We can all make a difference by donating blood. Each donation can benefit up to three people in emergency situations and for long-term medical treatments,” said Cristiano Ronaldo, forward for Real Madrid and Captain for Portugal National Football. “That’s why I am enthusiastic to be partnering with Abbott to bring awareness to the importance of blood donation and to encourage people around the world to become lifelong blood donors and help save lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7668251-abbott-cristiano-ronaldo-donate-blood/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The 1-year Full-Time MBA is the School’s flagship program with just about 100 MBA students. It is a challenging life time experience to learn the art of management and grow personally and professionally.
Full-Time MBA structure is organized around three cornerstones: Planning and Innovating, Controlling and Investing, Leading People and Processes. These core courses represent the competence requirements of a global manager.
To view the Multimedia News Release, go to http://www.multivu.com/players/uk/7674251-sda-bocconi-1-year-full-time-mba/
